INSTITUTIONAL REVIEW BOARD
The New York State Psychiatric Institute,
Columbia University Department of Psychiatry
1051 Riverside Drive
New York, NY 10032
|Edward Nunes, MD||Agnes Whitaker, MD|
Revised common rule new requirements: Effective January 21, 2019
**Only studies approved or altered after 1/21/19 will be governed the new rule.
For approved existing studies: the below noted consent form changes will need to be incorporated at the next Continuing Review or with the next Modification, whichever comes first.
New consent requirements:
Change #1. Four new required elements of consent. These new items of information must be included in the consent form or (if there is no consent form) covered during the consent process.
Required for all studies that collect identifiable private information or identifiable biospecimens
- A statement about whether subject’s private information or biospecimens could be used for future research studies or distributed to another investigator for future research studies, with or without identifiers.
Required when appropriate to the study
- A statement that the subject’s biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit.
- A statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions.
- For research involving biospecimens, whether the research will (or might) include whole genome sequencing (i.e., sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen).
Change #2. Key information. The consent form (or consent process, if there is no consent form) must begin with a concise and focused presentation of the key information that is most likely to assist a prospective subject in understanding the reasons why one might or might not want to participate in the research. This part of the consent form or process must be organized in a way that facilitates comprehension.
Key Information Elements
The image below displays the five elements identified in the preamble to the revised Final Rule (link is external) as suggested key information.
Change #3. Criteria for granting a waiver of consent. A new criterion has been added.
- No more than minimal risk to subjects.
- The research could not practicably be carried out without the waiver.
- The waiver will not adversely affect subjects’ rights and welfare.
- The subjects will be provided with any additional pertinent information after participation.
- NEW If the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format.
Change #4. Criteria for granting a waiver of documentation of consent. A third set of criteria has been added, meaning that there are three different reasons why a waiver of documentation of consent can be granted.
- The only record linking the subject and the research would be the informed consent form and the principal risk would be potential harm resulting from a breach of confidentiality. OR
- The research involves no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context. OR
- NEW If the subjects are members of a distinct cultural group or community in which signing forms is not the norm, the research involves no more than minimal risk of harm, and there is an appropriate alternative mechanism for documenting that consent was obtained.
Change #5. Posting of clinical trial consent form. For each clinical trial conducted or supported by a federal agency that has signed the revised Common Rule, one IRB approved consent form used to enroll subjects must be posted on a publicly available federal website that is established as a repository for such consent forms. This is the responsibility of the researcher or the federal agency.
Other changes under the revised rule:
Continuing Review is the requirement for the IRB to review a study annually and renew the IRB approval.
The change. The following types of studies will no longer need to go through Continuing Review at all. However, the NYSPI-IRB will require a brief progress report once a year.
- Studies whose initial application was reviewed by the “minimal risk” process, called expedited review
- Studies whose remaining research procedures consist solely of:
- Data analysis (including analysis of identifiable private information or identifiable biospecimens), and/or
- Obtaining clinical care data from records, for follow-up purposes
This does not apply to studies that are:
- Regulated by the Food and Drug Administration (FDA)
- Funded by the federal Department of Justice
Unlike all of the other changes, this change is implemented on January 20, 2020.
The change. For studies that involve more than one institution or organization, the same IRB must conduct the review for all of the institutions. This “Single IRB” requirement only applies to research that is funded by any of the federal agencies that adopted the revised Common Rule:
|Agency for International Development (USAID)||Department of Homeland Security|
|Central Intelligence Agency||Department of Housing and Urban Development|
|Consumer Product Safety Division||Department of Labor|
|Department of Agriculture||Department of Transportation|
|Department of Commerce||Department of Veterans Affairs (VA)|
|Department of Defense||Environmental Protection Agency (EPA)|
|Department of Education||National Aeronautics and Space Administration (NASA)|
|Department of Energy||National Science Foundation (NSF)|
|Department of Health and Human Services||Social Security Administration (SSA)|